Baird Medical Investment Holdings Ltd (BDMD) Form 424B3 — Aug 18, 2026
Baird Medical Investment Holdings (BDMD) filed a prospectus registering up to 34,415,562 ordinary shares for resale by selling securityholders, plus 11,500,000 shares issuable upon exercise of warrants struck at US$11.50 — together approximately 63.8% of issued and outstanding shares on a post-exercise basis. The company receives no proceeds from any resale. Insiders hold stakes acquired at prices as low as US$0.004 (Sponsor shares) and up to US$10.20 per share against a US$1.07 closing price on August 5, 2026, giving them a strong incentive to sell even at depressed levels and creating a major overhang for the stock.
Key figures
- Revenue
- US$22.5 million (FY2025); US$37.0 million (FY2024); US$31.5 million (FY2023)
- Net Income
- US$27.5 million net loss (FY2025); net income of US$12.6 million (FY2024) and US$10.7 million (FY2023)
- Gross Proceeds
- US$0 to the company from resale sales; up to US$132,250,000 only if all 11,500,000 warrants are exercised at US$11.50 (company deems this unlikely)
- Shares Offered
- 34,415,562 resale shares plus 11,500,000 shares issuable upon warrant exercise
- Shares Outstanding
- 42208763
- Sponsor share cost usd
- approximately US$0.004 per share (5,750,000 shares)
- Warrant exercise price usd
- 11.5
- Series a preferred outstanding
- 290000
- Cohen and gfc purchase price usd
- 10
- Grand forture purchase price usd
- 6.75
- Hospitals purchasing products 2025
- approximately 614 (from approximately 430 in 2022)
- Share closing price 2026 08 05 usd
- 1.07
- Warrant closing price 2026 08 05 usd
- 0.047
- Resale pct of outstanding post exercise
- approximately 63.8%
- Betters business combination share value usd
- 10.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.